Onctalk

New GRACE Post on Molecular Testing for EGFR: Should It Be Routine Practice?

Dr. West — Fri, 09 May 2008 06:36:37 +0000

There’s a new post at the GRACE website on the topic of whether oncologists should do molecular testing routinely for NSCLC tumors. This is the subject of a debate in which I’ll be participating in an upcoming meeting. You can read more about the topic here.

New Post in GRACE Lung Cancer Section

Dr. West — Wed, 07 May 2008 05:05:30 +0000

Dr. Laskin wrote a new post on the GRACE site, here, describing in some detail the negative ESCAPE trial of sorafenib with chemo for first line treatment of advanced NSCLC.

Although we’re mothballing the OncTalk site and not really adding to it, some people have noted that GRACE doesn’t yet offer a way to get alerts when new posts are written. That feature is in the works. In the meantime, I can write a brief note here that triggers an alert until we have the proper mechanism in place.

Biomarkers Predicting Clinical Benefits for BAC Patients Receiving Tarceva

Dr. West — Thu, 01 May 2008 06:35:48 +0000

The second post of the article on tarceva for advanced BAC, based on a clinical trial from Memorial Sloan Kettering Cancer Center, focuses on biomarkers correlated with better and worse results with tarceva. This post is available here on the GRACE website.

Trial of Tarceva in BAC: New Info on Who Benefits with Tarceva

Dr. West — Wed, 30 Apr 2008 01:53:46 +0000

I wrote a new post summarizing an interesting trial of tarceva (erlotinib) in bronchioloalveolar carcinoma, or BAC. It’s available on the GRACE website, here.

Cavitation of Lung Tumors on Anti-Angiogenic Agents

Dr. West — Mon, 28 Apr 2008 05:56:44 +0000

There is a new post on the GRACE website, available here, on the topic of tumor cavitation and potential risk during treatment with anti-angiogenic drugs for lung cancer.